DMAC
Price
$8.27
Change
+$0.07 (+0.85%)
Updated
Sep 30 closing price
Capitalization
448.66M
49 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$2.57
Change
-$0.02 (-0.77%)
Updated
Sep 30 closing price
Capitalization
385.49M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DMAC vs EDIT

DMAC vs EDIT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMAC vs. EDIT commentary
Oct 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a Buy and EDIT is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
DMAC vs EDIT: Fundamental Ratings
DMAC
EDIT
OUTLOOK RATING
1..100
397
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
34
Fair valued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3779
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is in the same range as DMAC (58). This means that EDIT’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (47) in the Biotechnology industry is somewhat better than the same rating for EDIT (100). This means that DMAC’s stock grew somewhat faster than EDIT’s over the last 12 months.

DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as EDIT (99). This means that DMAC’s stock grew similarly to EDIT’s over the last 12 months.

DMAC's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for EDIT (79). This means that DMAC’s stock grew somewhat faster than EDIT’s over the last 12 months.

DMAC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that DMAC’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMACEDIT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend about 1 month ago
80%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 01, 2026
Stock price -- (DMAC: $8.27 vs. EDIT: $2.57)
Brand notoriety: DMAC and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 144% vs. EDIT: 61%
Market capitalization -- DMAC: $448.66M vs. EDIT: $385.49M
DMAC [@Biotechnology] is valued at $448.66M. EDIT’s [@Biotechnology] market capitalization is $385.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green while EDIT’s FA Score has 0 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, DMAC is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 6 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • DMAC’s TA Score: 6 bullish, 4 bearish.
  • EDIT’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than EDIT.

Price Growth

DMAC (@Biotechnology) experienced а +9.39% price change this week, while EDIT (@Biotechnology) price change was -4.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.67%. For the same industry, the average monthly price growth was -10.91%, and the average quarterly price growth was +1.00%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 18, 2026.

EDIT is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-2.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DMAC
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GROV1.060.01
+0.95%
Grove Collaborative Holdings
IDCC326.071.77
+0.55%
InterDigital
BLZRU10.35N/A
N/A
Trailblazer Acquisition Corp Unit
SMA32.20-0.02
-0.06%
Smartstop Self Storage REIT Inc
VMD9.10-0.13
-1.41%
Viemed Healthcare

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with VIR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+0.85%
VIR - DMAC
43%
Loosely correlated
+4.98%
EDIT - DMAC
42%
Loosely correlated
-0.77%
ANNX - DMAC
42%
Loosely correlated
+2.42%
SLDB - DMAC
39%
Loosely correlated
+0.98%
PRME - DMAC
38%
Loosely correlated
-1.13%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with BEAM. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-0.77%
BEAM - EDIT
66%
Loosely correlated
-0.29%
CRBU - EDIT
65%
Loosely correlated
+2.42%
PRME - EDIT
63%
Loosely correlated
-1.13%
CRSP - EDIT
63%
Loosely correlated
-1.21%
VYGR - EDIT
60%
Loosely correlated
+1.52%
More